SPECIAL NOTICE
99 -- TECHNOLOGY/BUSINESS OPPORTUNITY High throughput discovery of linear B-cell epitopes for the development of vaccines and therapeutics
- Notice Date
- 3/27/2023 8:40:14 AM
- Notice Type
- Special Notice
- NAICS
- 334516
— Analytical Laboratory Instrument Manufacturing
- Contracting Office
- LLNS � DOE CONTRACTOR Livermore CA 94551 USA
- ZIP Code
- 94551
- Solicitation Number
- IL-13612
- Response Due
- 3/27/2023 9:00:00 AM
- Archive Date
- 04/28/2023
- Point of Contact
- Yash Vaishnav, Phone: 9254223538, Charlotte Eng, Phone: 9254221905
- E-Mail Address
-
vaishnav1@llnl.gov, eng23@llnl.gov
(vaishnav1@llnl.gov, eng23@llnl.gov)
- Description
- Opportunity: Lawrence Livermore National Laboratory (LLNL), operated by the Lawrence Livermore National Security (LLNS), LLC under contract no. DE-AC52-07NA27344 (Contract 44) with the U.S. Department of Energy (DOE), is offering the opportunity to enter into a collaboration to further develop and commercialize its technology for high throughput discovery of linear B-cell epitopes for the development of vaccines and therapeutics. Background: Our humoral immune response is mediated by antibodies and triggered when antigens are detected through the binding of their B-cell epitopes to surface receptors of B lymphocytes. �Most B-cell epitopes are conformational, formed by non-contiguous amino acid residues brought together by complex folding of the antigen. However, a small fraction are linear epitopes that are simpler, linear stretches of amino acid residues. Linear B-cell epitopes are ideal candidates in aiding vaccine formulation since they can trigger an immune response without proper folding and complex 3D conformation requirements. � Synthetic peptides containing B-cell epitopes administered to animals have shown to stimulate their immune system to secrete antibodies that recognize antigens from which these epitopes are derived.� Therefore, the use of multiple synthetic peptides in formulating a vaccine is a highly promising approach in the development of subunit vaccines. These peptide-based vaccines have many advantages, including being both safer and more cost effective than attenuated and inactivated vaccines.� Several peptide-based vaccines are currently under development for the prevention of infectious diseases such as malaria, influenza, and HIV. �However, to identify B-cell epitope candidates rapidly and efficiently remains a formidable challenge.� Current identification strategies tend to involve the experimental detection of epitopes on a single protein, which are low throughput (one protein at a time) and require initial knowledge of the antigen and its sequence. High throughput strategies are available, but they require extensive use of synthetic biology and other time-consuming methodologies, e.g., library construction, peptide/protein array preparation and expression of proteins using non-native expression systems. A more practical approach to characterize B-cell epitopes for peptide-based vaccine formulation would have to be simple, efficient, cost-effective and high throughput. ��Researchers at LLNL have developed a shotgun immunoproteomic approach that can fulfil these requirements while also be broadly applicable to the identification of linear B-cell epitopes from any pathogen. Description: LLNL�s high throughput method involves proteome-wide screening for linear B-cell epitopes using native proteomes isolated from a pathogen of interest and convalescent sera from immunized animals. LLNL researchers have applied their newly developed generalizable screening method to the identification of pathogenic bacteria by screening linear B-cell epitopes in the proteome of Francisella tularensis as well as Burkholderia pseudomallei; both are considered Tier 1 Select Agents by the Centers for Disease Control and Prevention. �The results from these two test cases showed the screening method was successful in identifying peptides that map to known antigens of these infectious organisms.� LLNL�s novel immunoproteome screening method used in the test cases can easily be adapted to detecting peptide targets relevant to the immune systems of other mammalian species, including humans (depending upon the availability of convalescent sera from patients), and could aid in accelerating the discovery of B-cell epitopes and development of effective vaccines and therapeutics for a variety of diseases. Advantages/Benefits:� LLNL�s method for epitope discovery has many advantages: Is a high throughput method. Prior knowledge of antigenicity and structural information not required. Does not involve laborious experimental techniques as compared to technologies currently available. Designed to provide not only the protein antigen identification, but (more importantly) also delineate the antigenic regions of the identified antigens (epitopes). Facilitate development of peptide-based vaccines, which are safer and more cost effective than attenuated and inactivated vaccines Potential Applications:�� Peptide-based vaccine and therapeutic development to counter biothreat agents, emerging pathogens and other pathogens of interest Development Status:� LLNL has filed for patent protection on this invention. U.S. Patent Application Publication No. 2022/0238183 NOVEL METHODS FOR RAPID DETECTION OF IMMUNOGENIC EPITOPES IN BIOTHREAT AGENTS AND EMERGING PATHOGENS FOR PEPTIDE VACCINES AND THERAPEUTICS published 7/28/2022 Current stage of technology development:� TRL-2 LLNL is seeking industry partners with a demonstrated ability to bring such inventions to the market. Moving critical technology beyond the Laboratory to the commercial world helps our licensees gain a competitive edge in the marketplace. All licensing activities are conducted under policies relating to the strict nondisclosure of company proprietary information.� Please visit the IPO website at https://ipo.llnl.gov/resources for more information on working with LLNL and the industrial partnering and technology transfer process. Note:� THIS IS NOT A PROCUREMENT.� Companies interested in commercializing LLNL's high throughput discovery of linear B-cell epitopes for the development of vaccines and therapeutics should provide a written statement of interest, which includes the following: 1.�������� Company Name and address. 2.�������� The name, address, and telephone number of a point of contact. 3.� � � � �A description of corporate expertise and/or facilities relevant to commercializing this technology. Written responses should be directed to: Lawrence Livermore National Laboratory Innovation and Partnerships Office P.O. Box 808, L-779 Livermore, CA� 94551-0808 Attention:�� IL-13612 Please provide your written statement within thirty (30) days from the date this announcement is published to ensure consideration of your interest in LLNL's high throughput discovery of linear B-cell epitopes for the development of vaccines and therapeutics.
- Web Link
-
SAM.gov Permalink
(https://sam.gov/opp/0488cfa926674ea18284ebd3039aaeb5/view)
- Place of Performance
- Address: Livermore, CA, USA
- Country: USA
- Country: USA
- Record
- SN06630778-F 20230329/230327230104 (samdaily.us)
- Source
-
SAM.gov Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's SAM Daily Index Page |